Navigation Links
Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
Date:8/26/2010

CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Sermo (http://www.sermo.com/client), the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS).  According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor.

The Sermo Report polled 60 physicians, many of who also participated in a discussion about the treatment. Acute coronary syndrome (ACS) incorporates a number of symptoms consistent with the probability that a patient is suffering from active Myocardial Infarction. Competitors to ticagrelor include Bristol-Myers Squibb Co. and Sanofi-Aventis', Plavix and Effient, sold by Eli Lilly & Company.

"Physicians on Sermo see ticagrelor as significantly impactful to clinicians," said Adam Sharp, Chief Medical Officer at Sermo. "However, cost and time in market could slow adoption. While more research on physician awareness still needs to be done, it's also interesting to note that 50% of docs did not know about the FDA approval before seeing it on Sermo."

Highlights from the report include:

  • Cost, time in market and generic Plavix were identified as three issues that could dissuade physicians from writing ticagrelor.
  • Reversibility and less post-operative bleeding were identified as possible advantages of this medication over Plavix.

Physicians shared their views of ticagrelor:

"While cost is certainly an issue we deal with all the time (can't wait until Plavix goes generic), there are some advantages with this medication – the biggest being the reversibility. I would be curious to see in the future how cardiac surgeons feel when this drug is in use – will they find that the drug really is reversible and that they find less post-operative bleeding. This would be a clear benefit over Plavix."

--Cardiologist, Sermo physician

"I would wait for a year or two to start prescribing it systematically. This time should be sufficient to elucidate the side-effect profile of the drug."

---Critical Care, Sermo physician

The full Sermo report includes key findings, MD demographics and post analysis.

Download the free report at http://www.sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about drugs, devices, treatments, and trends. Data for Sermo Reports are gathered through Sermo Posts, which allow physicians to participate in a poll and discussion about the topic.

About Sermo

Sermo is the largest online physician community, where over 115,000 practicing physicians discuss clinical cases and get advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit http://www.sermo.com/clients.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
2. NCPA: AARP Report Finds Brand Name Drug Prices Soar as Large Pharmacy Benefit Managers Reap Windfall Profits
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Kewaunee Scientific Reports Sales and Earnings for First Quarter
7. Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market
8. Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute lymphocytic Leukemia Market ... to their offering.       (Logo: ... Acute Lymphocytic Leukemia Market and Competitive Landscape ... Lymphocytic Leukemia pipeline products, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... , ... A new collaboration will give more researchers access to the largest ... analytics leader SAS will provide researchers worldwide with data management and analytics tools to ... , The DCRI and SAS share the goal of greater transparency and openness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her ... surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight was ...
(Date:5/4/2016)... ... 2016 , ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned ... a free seminar on stem cell injections. The seminar is scheduled for Wednesday, May ... Telephone Road, Suite 110, Ventura, CA. There are only 10 seats available. , ...
(Date:5/4/2016)... Lenexa, KS (PRWEB) , ... May 04, 2016 ... ... Transtem™ Patient 2016, a powerful cellular therapy software application that helps ... life-saving treatments to patients. , Since Transtem’s initial launch, Mediware has continued to ...
Breaking Medicine News(10 mins):